<DOC>
	<DOCNO>NCT00022087</DOCNO>
	<brief_summary>RATIONALE : Zoledronate plus calcium vitamin D may prevent bone loss patient receive adjuvant chemotherapy breast cancer . It yet know regimen effective prevent bone loss . PURPOSE : This randomized phase III trial compare two regimen zoledronate plus calcium vitamin D see well work prevent bone loss woman receive adjuvant chemotherapy breast cancer .</brief_summary>
	<brief_title>Zoledronate , Calcium , Vitamin D Preventing Bone Loss Women Receiving Adjuvant Chemotherapy Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare bone mineral density lumbar spine 12 36 month therapy zoledronate , calcium , cholecalciferol ( vitamin D ) woman breast cancer receive adjuvant chemotherapy . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord intent treat tamoxifen ( yes v ) node status ( negative v positive v unknown [ patient receive neoadjuvant therapy ] ) . Patients randomize 1 2 treatment arm . - Arm I : Beginning first day adjuvant chemotherapy ( within 3 month first day ) , patient receive zoledronate IV least 15 minute every 3 month month 1-24 oral calcium oral cholecalciferol ( vitamin D ) daily month 1-36 . - Arm II : Beginning first day adjuvant chemotherapy ( within 3 month first day ) , patient receive oral calcium oral vitamin D daily month 1-36 zoledronate IV least 15 minute every 3 month month 13-36 . PROJECTED ACCRUAL : Approximately 400 patient ( 200 per treatment arm ) accrue study within 24 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast fine needle aspirate , biopsy ( trucut , core , stereotactic ) , lumpectomy , modify radical mastectomy Stage IIII ( T , N , M0 ) Stage IV due solely supraclavicular node involvement allow Plan use adjuvant chemotherapy* without adjuvant endocrine therapy* Subsequent adjuvant hormonal therapy aromatase inhibitor allow woman render postmenopausal adjuvant chemotherapy NOTE : *Must specify prior study entry Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 40 Sex : Female Menopausal status : See Disease Characteristics Premenopausal , define actively menstruate last menstrual period occur within 6 month prior study entry Prior hysterectomy without bilateral oophorectomy estradiol folliclestimulating hormone within premenopausal range prior initiation chemotherapy allow Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No 3 month since prior adjuvant chemotherapy Endocrine therapy : See Disease Characteristics Radiotherapy : Not specify Surgery : See Disease Characteristics See Menopausal status Other : No concurrent bisphosphonates No concurrent digoxin No concurrent tetracycline Concurrent neoadjuvant therapy allow Concurrent enrollment therapeutic adjuvant clinical trial allow provide therapeutic trial preclude participation trial</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>